GSEP
CYTK icon

Golden State Equity Partners’s Cytokinetics CYTK Stock Holding History

Golden State Equity Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30
Closed -$1.98K – 645
2026
Q1 		$1.98K Buy
+30
New +$1.91K ﹤0.01% 1679

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Golden State Equity Partners's CYTK Position: Q2 2026 in Review

Golden State Equity Partners sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 30 shares — an estimated $1.98K sold.

Golden State Equity Partners first reported a position in CYTK in Q1 2026 and held it in 1 quarter. The position peaked at $1.98K in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Golden State Equity Partners reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 30 Cytokinetics shares in Q2 2026, an estimated $1.98K.
  • Golden State Equity Partners first reported a position in Cytokinetics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Cytokinetics position peaked at $1.98K in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.